Today: 5 February 2026
Subscribe
Browse Category

TSX:VZLA News 28 December 2025 - 29 December 2025

Vizsla Silver dips in premarket as silver pulls back from its $80 spike

Vizsla Silver dips in premarket as silver pulls back from its $80 spike

NEW YORK, December 29, 2025, 04:29 ET — Premarket Vizsla Silver Corp shares fell 1.9% to $5.81 in U.S. premarket trading on Monday, after closing at $5.92 in the prior session, market data showed. Public The move matters because the stock often tracks silver prices, which have turned sharply volatile after a run to record highs that pulled more money…
29 December 2025
····
Vizsla Silver Corp. (VZLA) Stock Near 52-Week High as Silver Hits Record — What Investors Should Watch Before Monday’s Open

Vizsla Silver Corp. (VZLA) Stock Near 52-Week High as Silver Hits Record — What Investors Should Watch Before Monday’s Open

NEW YORK, Dec. 27, 2025, 6:54 p.m. ET — Market closed Vizsla Silver Corp. (NYSE American: VZLA; TSX: VZLA) heads into the final week of 2025 with momentum on its side, after the stock finished Friday’s session higher and just shy of its 52-week high as precious metals surged and U.S. equities held near record territory. VZLA closed Friday at…
28 December 2025
······

Stock Market Today

  • Boston Scientific Shares Dive 17.5% on Disappointing 2026 Profit Guidance
    February 4, 2026, 6:32 PM EST. Boston Scientific's stock plunged 17.5% to $75.59 on Feb. 4 after its Q4 earnings beat estimates but cautious 2026 profit guidance disappointed investors. The medical-device maker delivered 16% sales growth and 14% adjusted EPS growth in Q4, outperforming Wall Street expectations. However, weak guidance for the first quarter and 2026 EPS trimmed investor optimism, with EPS projections falling slightly short. Trading volume surged 581% above its three-month average, reflecting the sharp selloff. Despite the setback, Boston Scientific's Cardiovascular segment grew sales 18%, MedSurg unit revenues rose 12%, and management forecasted $4.2 billion in free cash flow for 2026. The decline was company-specific; peers Medtronic and Stryker showed smaller losses. Investors weigh today's reaction as overdone given Boston Scientific's consistent long-term growth and double-digit sales gains across 12 quarters.
Go toTop